Skip to main content

inclisiran (Leqvio®)


Appraisal in progress


Status: In progress

In adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid‑lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin, or; alone or in combination with other lipid‑lowering therapies in patients who are statin‑intolerant, or for whom a statin is contraindicated.

Medicine details

Medicine name inclisiran (Leqvio®)
Formulation 284 mg solution for injection
Reference number 3746

As above

Company Novartis Pharmaceuticals UK Ltd
BNF chapter Cardiovascular system
Submission type Full
Status In progress
NMG meeting date 05/01/2022
AWMSG meeting date 09/02/2022
Date of issue TBC